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Background/Aims: Recent reports suggest that the adipose tissue and adipokines are potent modulators of
inflammation. However, there is only scarce knowledge on the functional role and regulation of endogenous adiponectin
in non-fat tissues such as the liver under conditions of acute inflammation.
Methods: In the present study, we investigated adiponectin expression in healthy murine liver tissue and under
inflammatory conditions in vivo.
Results: Adiponectin mRNA was readily detectable in healthy liver tissue and further increased in ConA-mediated
acute liver failure. Adiponectin protein expression was mainly found in hepatic endothelial cells. In vitro adiponectin
mRNA expression was detectable in several cell types, including primary hepatic sinusoidal endothelial cells, stellate
cells, and macrophages. Mice pretreated with adiponectin before ConA administration developed reduced hepatic
injury as shown by decreased release of transaminases and reduced hepatocellular apoptotis. Of note, TNF-a levels
were not affected by adiponectin, whereas IL-10 production was increased. Neutralisation of IL-10 diminished the
protective effect of adiponectin.
Conclusions: Adiponectin expression is up-regulated in ConA-mediated acute liver failure. Therefore, adiponectin
might play a role in the control and limitation of inflammation in the liver. Moreover, our data suggest a role for IL-10
in adiponectin-mediated hepatoprotection.
q 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Only recently, with the discovery of a variety of
adipocyte-derived cytokines, so called ‘adipokines’, the
adipose tissue has gained a role as an important endocrine
organ. Adiponectin has attracted much interest as it
represents the most abundant adipocyte-derived protein
reaching high plasma levels in both humans and rodents [1].0168-8278/$30.00 q 2005 European Association for the Study of the Liver. Pub
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E-mail address: herbert.tilg@uibk.ac.at (H. Tilg).Adiponectin has been shown to elicit a broad range of
biological effects such as insulin-sensitising and anti-
atherogenic actions [2].
Recent reports pointed out to a possible role of adipose
tissue and adipokines as potent regulators of inflammatory
processes. We and others recently demonstrated potent anti-
inflammatory properties of adiponectin [3,4]. Apart from
downregulation of the synthesis of the pro-inflammatory
cytokine TNF-a, adiponectin leads to an increased
production of the anti-inflammatory mediators IL-10 and
IL-1RA in human myeloid cells [3]. Adiponectin seems to
be primarily expressed by adipocytes. Thus, regulation of
adiponectin expression has been almost exclusively studied
in adipocytes. However, recent reports showed that in
human myotubes expression of adiponectin can be inducedJournal of Hepatology 44 (2006) 537–543www.elsevier.com/locate/jheplished by Elsevier B.V. All rights reserved.
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TNF-a or LPS [5,6]. This observation might describe a
negative feedback-loop mediated via adiponectin and fits
into the concept that adiponectin plays an anti-inflammatory
role in inflammation. However, there is only scarce
knowledge on the functional role and regulation of
endogenous adiponectin and its receptors in non-fat tissues
such as the liver under conditions of acute inflammation.
Therefore, the aim of the present work was to (I) examine
whether adiponectin could be detected in normal healthy
liver tissue, (II) to further characterize adiponectin
producing cell types and (III) to find out, if adiponectin
exerts hepatoprotective effects in a model of acute liver
failure.2. Materials and methods2.1. Animals
Six to 8-week-old female BALB/c mice were obtained from Harlan
(Borchen, Germany) and were maintained under controlled conditions
(22 8C, 55% humidity, 12-h dark/light rhythm), having free access to
standard chow and water. All animals received humane care according to
the legal requirements in Austria.2.2. Animal treatments
All reagents were injected in a total volume of 200 ml per mouse for
intravenous injections (i.v.) and 100 ml per mouse for intraperitoneal (i.p.)
injections and were dissolved in pyrogen-free saline. Where indicated
either 6 mg/kg murine Adiponectin (R&D systems) or saline were i.p.
injected 12 h before treatment with 15 mg/kg Con A (Sigma, Vienna,
Austria) i.v. To investigate the role of IL-10 in adiponectin induced
hepatoprotection, either 3 mg of neutralizing IL-10 antibody per mouse
(Immunotools, Friesoythe, Germany) or solvent was administrated 30 min
before adiponectin injection.2.3. Sampling of material
For determination of circulating cytokine levels, blood samples were
taken from the tail-vein 2 h after challenge. Eight hours after ConA-
treatment, mice were lethally anesthetized with 50 mg/kg Vetanarcol
(Intervet, Austria) i.v., containing a dose of 15 mg/kg heparin. Blood was
withdrawn by cardiac puncture, immediately centrifuged and plasma
samples were stored at K20 8C. The livers were removed and one part was
frozen in liquid nitrogen for mRNA preparation, another part was
embedded in Tissue-TEK and stored at K20 8C until staining. Primary
macrophages were magnetically selected from minced liver tissue by
CD11b beads (Miltenyi Biotec, Bergisch Gladbach, Germany).2.4. Primary liver cells
Primary hepatocytes, hepatic stellate cells (HSC) and hepatic sinusoidal
endothelial cells (HSEC) were purchased from Pharmakine (Bilbao, Spain).2.5. Cytokine determination by ELISA
Detection of TNF-a, IL-6 and IL-10 in plasma samples was performed
strictly according to the manufacturer’s instructions using mouse specific
monoclonal antibody (mAb) pairs purchased from BD Pharmingen (San
Diego, CA).2.6. Cytokine determination by cytometric bead array
(CBA)
TNF-a, IL-6, and IL-10 in plasma samples were determined using the
mouse inflammation kit CBA purchased from BD Pharmingen (San Diego,
CA). Analyses were performed strictly according to the manufacturer’s
instructions.2.7. Analysis of liver enzymes
Liver injury was quantified by measurement of plasma enzyme
activities of ALT and AST using an automated procedure.2.8. Real-time RT-PCR for TNF-a, IL-10, adiponectin,
AdipoR1 and AdipoR2 mRNA
Total RNA was prepared from liver tissue using Trizol reagent
(Invitrogen, Paisley, UK). One microgram of RNA was employed for
synthesis of cDNA using random hexamers (Roche, Mannheim, Germany)
and MMLV reverse transcriptase (GIBCO, Gaithersburg, MD) strictly
according to the manufacturer’s instructions. Primers and TaqManw Probes
specific for TNF-a and IL-10 were obtained from TaqManw Pre-Developed
Assay Reagents (Applied Biosystems, Foster City, CA). For adiponectin,
AdipoR1 and AdipoR2 primers and probes were as follows:
5 0-CCGGAACCCCTGGCAG-3 0, 5 0-CCGGAACCCCTGGCAG-3 0,
FAM-AAAGGAGAGC CTGGAGAAGCCGCTT-TAMRA, 5 0-
CACTTCCCATGTGCATTCCC-3 0, 5 0-CCCACG TCCTATCTGT-
GAAGG-3 0, FAM-ACCTCGGCAAGGCAACTGCTGC-TAMRA, and
5 0-AGGAG TGTTCGTGGGCTTAGG-3 0, 5 0-CAGCCTTCAG-
GAACCCTT CTG-30, FAM-TGAGTGGAATCATCCCTACCTTGCAT-
TATGTC-TAMRA. For endogenous control, the level of GUS expression
in each sample was assayed using mouse GUS Pre-developed TaqManw
Control Reagents (Applied Biosystems, Foster City, CA). Quantitative real-
time RT-PCR was performed using the ABI PRISM 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA). Real-time PCR
efficiencies were acquired by amplification of a standardized dilution series
of subcutaneous fat (adiponectin), muscle (adipoR1), or liver (adipoR2)
cDNA from a Con A-challenged control mouse. The respective cDNAs
were further used as controls and arbitrarily set as 1.2.9. DNA fragmentation
In situ detection of DNA fragments was performed using a terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end
labeling (TUNEL) test (Roche, Mannheim, Germany).2.9.1. Immunohistochemical and immunofluorescence
stainings
Paraffin sections were deparaffinized, rehydrated and pretreated
with antigen unmasking solution (Vector, Burlingame, CA, 8 min)
followed by blocking with peroxidase blocking reagent (DAKO,
Carpinteria, CA) and 3% goat serum (Vector, ABC-Elite kit). The
sections were then incubated overnight with the polyclonal goat anti-
mouse adiponectin antibody (diluted 1:1000, RnD systems) followed
by a biotinylated anti-goat secondary antibody for 30 min (Vector,
ABC-Elite-Kit) and incubation with the avidin-peroxidase complex
(Vector, Burlingame, CA). Colour was developed using the DAB
substrate and sections were counterstained with hematoxylin (Vector,
Burlingame, CA). Cryostat sections were fixed in acetone for 10 min
and stained using the first and secondary antibodies as described
above. Subsequently, the sections were incubated with streptavidin-
TexasRed (Vector, Burlingame, CA). Double stainings using CD31
and MECA-32 (BD Pharmingen) antibodies followed by a FITC-
labeled anti-rat antibody (DAKO) were performed. A negative control
section was always included in which the primary antibody was
substituted by the corresponding isotype control. The sections were
analyzed without prior knowledge of treatment, and treatment
response. The density of adiponectinC cells was evaluated by
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l] 2.10. NF-kB activity
NF-kB activation was measured using the EZ-Detect NF-kB p65
Transcription Factor Kit (Pierce, Rockford, USA) strictly according to the
manufacturer’s instructions.B
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 2.11. Statistical analysis
Results are expressed as the meanGSEM. Statistical analyses were
performed using Student’s t-test. A value of P%0.05 was considered
significant. Statistical analysis was performed using the GraphPadPrism
software.C
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Fig. 1. Adiponectin mRNA is detectable in healthy murine liver tissue
and is upregulated upon ConA injection. Mice were challenged either
with saline or ConA (15 mg/kg, nZ5 per group). (A) Hepatic
adiponectin, (B) AdipoR1 and AdipoR2 (C) mRNA levels were
determined by real-time PCR 8 h after ConA injection (*P%0.05).3. Results
3.1. Adiponectin and its receptors are expressed in healthy
liver tissue and regulated upon injection of ConA
In healthy murine livers, we found a low but clearly
detectable basal expression of adiponectin (Fig. 1(A)). It
is noteworthy that special care was taken while preparing
liver tissue for mRNA-isolation to avoid any contami-
nation with mesenteric fat tissue. We further detected
abundant expression of adiponectin receptor 1 and 2
(AdipoR1 and AdipoR2) mRNA, respectively (Fig. 1(B)
and (C)). We next focussed on adiponectin expression
under conditions of acute hepatic inflammation. Therefore,
mice were injected with 15 mg/kg ConA. Real-time PCR
revealed a 2.2G0.6 fold increase of adiponectin mRNA
expression within 8 h after challenge (*P%0.05). In
contrast, acute hepatic inflammation reduced AdipoR1
and AdipoR2 mRNA expression levels to 30 and 60%,
respectively, when compared to healthy control livers
(*P%0.05).3.2. Adiponectin is expressed by endothelial cells
and hepatocytes in healthy and inflamed liver tissue
To investigate whether the observed increase of
adiponectin mRNA was accompanied by increased
adiponectin protein levels, we performed immunohisto-
chemical stainings of healthy as well as ConA-injected
mouse livers. Adiponectin-expressing cells exhibit an
endothelial cell-like phenotype (Fig. 2(A)). In line with
the mRNA data, ConA-injection led to an increased
number of adiponectin positive cells (Fig. 2(B) and
(C)). To further define the adiponectin-producing cell
type, we performed immunofluorescence double-stain-
ings. Adiponectin positive cells, at least in part, stained
positive for the endothelial cell markers CD31
(Fig. 2(E) and (F)) and MECA-32 (Fig. 2(G)).Fig. 2(D) and (H) depict the corresponding isotype
control.3.3. Detection of adiponectin mRNA in isolated primary
hepatocytes, hepatic sinusoidal endothelial cells, stellate
cells and macrophages.
To investigate in more detail the hepatic adiponectin-
expressing cell-types we analysed adiponectin expression
by quantitative RT-PCR in several hepatic cell types.
According to our immunofluorescence and immunohisto-
chemical stainings we detected adiponectin mRNA in
isolated primary murine hepatic sinusoidal endothelial
cells as well as in primary hepatic stellate cells (Fig. 3).
Additionally, adiponectin mRNA was also found in
CD11b-selected primary hepatic macrophages. No
Fig. 2. Adiponectin is expressed by hepatic CD31C, MECA-32C
endothelial cells. Paraffinized tissue sections from ConA- and
saline-injected animals were stained for adiponectin. (A) Basal
hepatic adiponectin expression in healthy animals was detected in
cells showing an endothelial phenotype (see arrow). (B and C)
Increased adiponectin expression was detectable in ConA-injected
mice (magnification !100). Immunofluorescence staining revealed
that adiponectin-positive cells (red staining) co-expressed endo-
thelial cell markers such as CD31 (E and F) and MECA-32 (G)
(magnification !400). (D and H) show the corresponding isotype
control. A representative example out of three is shown.
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Fig. 3. Detection of adiponectin mRNA in isolated primary hepatic
stellate cells, hepatic sinusoidal endothelial cells, and liver macro-
phages. mRNA was obtained from isolated primary hepatocytes,
hepatic stellate cells, hepatic sinusoidal endothelial cells, and CD11b-
selected macrophages and adiponectin expression levels were deter-
mined by real-time PCR. Tissue expression levels are given relative to a
positive control as described in the Section 2.
A.M. Wolf et al. / Journal of Hepatology 44 (2006) 537–543540adiponectin mRNA was detected in isolated primary
mouse hepatocytes.3.4. Hepatoprotective effect of adiponectin
in ConA-induced acute liver failure
As adiponectin is known to decrease TNF-a
expression in macrophages [7] and to increase the
production of anti-inflammatory cytokines we next
aimed to analyze the impact of adiponectin on TNF-
dependent acute liver failure. Therefore, we eitherinjected 6 mg/kg recombinant murine adiponectin or
solvent 12 h prior to application of ConA. Adiponectin
pre-treatment significantly decreased the ConA-induced
hepatotoxicity as shown by release of liver enzymes
(Fig. 4(A), *P%0.05). These data were corroborated by
a lower number of TUNEL-positive apoptotic hepatic
cells (Fig. 4(B)). Using cytometric bead arrays and
ELISA we were not able to detect significant changes in
plasma levels of TNF-a and IL-6 (Fig. 4(C) and (D)).
However, IL-10 production was significantly increased
in adiponectin-treated mice (Fig. 4(E), *P%0.05).
Comparable results were obtained for hepatic mRNA
regulation as determined by quantitative RT-PCR:
Adiponectin did not change hepatic TNF-a mRNA
expression, whereas IL-10 mRNA expression was
increased by adiponectin (data not shown). Thus, the
protective effect of adiponectin administration in this
model does not appear to be mediated by reduced intra-
hepatic TNF-a levels.3.5. The hepatoprotective effect of adiponectin
is partially mediated by IL-10
We next tested whether the induction of IL-10 is causally
involved in adiponectin-induced hepatoprotection. There-
fore, animals were injected with a neutralizing antibody
directed against IL-10 prior to either adiponectin- or ConA-
injection. In line with previous reports, neutralisation of IL-
10 resulted in increased ConA-induced TNF-a production
(Fig. 5(A), P!0.05). Notably, anti-IL-10 treatment in part
abrogated the hepatoprotective effects of adiponectin as
shown by liver enzyme release: in contrast to the significant
reduction of ALT release by adiponectin, ALT levels in the
anti-IL10 pre-treated group did not statistically differ from
the saline/ConA control group (Fig. 5(B), *P%0.05 for
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Fig. 4. Hepatoprotective effect of adiponectin in ConA-induced acute liver failure. Either adiponectin or saline-pre-treated mice were challenged with
Con A (15 mg/kg, nZ8 per group). (A) Plasma ALT-levels were determined 8 h after Con A injection (*P%0.05). (B) Adiponectin markedly reduced
the induction of apoptosis detected by TUNEL-staining 8 h after challenge. A representative example from each group is shown (magnification !100).
(C) TNF-a, and (D) IL-6 plasma levels were determined 2 h and (E) IL-10 plasma levels (*P!0.05) were determined 8 h after ConA injection by
ELISA.
A.M. Wolf et al. / Journal of Hepatology 44 (2006) 537–543 541Adipo/ConA vs. saline/ConA and PO0.05 for a-IL10/
Adipo/ConA vs. saline/ConA).3.6. The ConA-mediated hepatic NF-kB activation
is significantly down-regulated by adiponectin
NF-kB represents a key transcription factor for the
regulation of ConA-induced cytokine gene expression [8].
We, therefore, analyzed the activation of NF-kB p65 upon
ConA-injection in mice pre-treated with either adiponectin
or solvent. Indeed, ConA-mediated activation of NF-kB wassignificantly inhibited by adiponectin pre-exposure (Fig. 6,
*P%0.05).4. Discussion
Adiponectin, the most abundant adipokine in humans,
has recently been shown to exert potent anti-inflammatory
effects in humans and in mice. To date, the regulation of
adiponectin has been nearly exclusively studied in the
adipocyte, which has been considered the unique site of
adiponectin production under physiological conditions [9].
However, two recent studies reported that adiponectin gene
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Fig. 5. The hepatoprotective effect of adiponectin is partially mediated
by IL-10. Either adiponectin/ConA or saline/ConA treated mice were
pre-treated with a neutralizing IL-10 antibody (3 mg/mouse, nZ4 per
group) followed by ConA injection. (A) Plasma TNF-levels were
determined 2 h after ConA injection by ELISA (B) Plasma ALT-levels
were determined 8 h after ConA injection (*P!0.05).
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lation with pro-inflammatory cytokines, such as IFN-g and
TNF-a [5,6]. In the current study, we show that apart from
high expression in adipose tissue, adiponectin is also
expressed in non-inflammatory murine liver tissue. Real-0
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Fig. 6. Down-regulation of ConA-mediated hepatic NF-kB activation
by adiponectin. Whole liver lysates were prepared from either
adiponectin/ConA- or saline/ConA-treated mice and NF-kB p65
activation was determined using a chemiluminescent assay (nZ4,
*P%0.05).time PCR revealed that adiponectin mRNA is produced in
several cells types i.e. isolated primary murine liver
sinusoidal endothelial cells, hepatic stellate cells and liver
macrophages. Induction of acute hepatic inflammation by
ConA led to a significant up-regulation of adiponectin.
These data are corroborated by a recent report from Yoda-
Murakami and co-workers showing an increase of adipo-
nectin in inflamed liver tissue induced by injection of CCl4
[10]. ConA-induced hepatic inflammation is characterized
by highly elevated systemic as well as hepatic TNF-a levels
[11]. In addition, adiponectin has been shown to be a major
antagonist of TNF-a production in several cell types [7,12].
Thus, its induction under conditions of acute inflammation
within hepatic tissue might counteract the pro-inflammatory
actions of TNF-a thereby forming a negative feedback loop
attempting to counterbalance hepatic inflammation in vivo.
In line with this idea, Maeda and co-workers recently
demonstrated that adiponectin-deficient mice revealed high
levels of TNF-a mRNA in adipose tissue as well as high
plasma TNF-a concentration [13]. Moreover, adiponectin-
treatment protects KK-Ay obese mice, which are charac-
terized by low circulating adiponectin levels from TNF-a-
mediated acute hepatic failure induced by LPS [12]. The
authors nicely demonstrate that the protective effect of
adiponectin in KK-Ay obese mice is primarily mediated by
down-regulating the sensitivity of hepatocytes to TNF-
induced apoptosis, without affecting cytokine levels in these
animals.
We extend these findings by showing that application of
adiponectin to BALB/c mice markedly attenuated liver
inflammation induced by ConA. In line with the findings
from Sennello and co-workers [14], we were not able to
detect a down-regulation of either circulating or hepatic
TNF-a levels. Therefore, adiponectin probably exerts its
hepatoprotective effects in the model of acute liver
inflammation induced by ConA by a mechanism indepen-
dent of TNF-a down-regulation. We and others recently
described an anti-inflammatory role of adiponectin on
in vitro cultured myeloid cells [3,4,7]. Pre-treatment of
monocytes and monocyte-derived cells (i.e. macrophages
and dendritic cells) with adiponectin impairs the LPS-
induced production of pro-inflammatory cytokines. This
effect is paralleled by an increased production of anti-
inflammatory cytokines, such as IL-10. Accordingly,
adiponectin pre-treatment significantly increased IL-10
production in ConA-injected animals. Blocking IL-10 by
neutralizing antibodies partially reversed the beneficial
effects of adiponectin in vivo. Thus, induction of IL-10
seems to play at least a partial role in the protective effects
of adiponectin. The TNF-a/NF-kB pathway plays a critical
role in inflammatory signaling processes. Adiponectin was
demonstrated to suppress TNF-a-induced activation of
nuclear factor-kB (NF-kB) in endothelial cells, therefore,
acting as an endogenous biologically relevant modulator of
endothelial cell responses to pro-inflammatory stimuli [15].
Moreover, adiponectin has been shown to inhibit
A.M. Wolf et al. / Journal of Hepatology 44 (2006) 537–543 543LPS-induced activation of NF-kB in adipocyte cell lines.
According to this data, adiponectin inhibited hepatic NF-kB
signaling in ConA-induced acute liver failure. Recent
reports demonstrated that hepatoprotective and anti-
apoptotic molecules such as S-Adenosylmethionine
and PGE1 may reduce NF-kB activation in hepatocytes
[16,17]. However, further signaling pathways being
involved in the anti-apoptotic effects of adiponectin in
hepatocytes remain to be elucidated. The activation of the
AMP-kinase for example has been shown to be involved in
protection from mitogen-deprivation induced cell death in
HUVEC [18].
In conclusion, our data clearly show that under
inflammatory conditions adiponectin can be produced by
other cell types, i.e. by hepatic endothelial and stellate
cells. Application of adiponectin decreases hepatic
injury, which suggests that adiponectin may play an
important role in the control and limitation of
inflammatory processes in the liver.Acknowledgements
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